<DOC>
	<DOCNO>NCT01269203</DOCNO>
	<brief_summary>The goal clinical research study learn curcumin reduce symptom report patient multiple myeloma ( MM ) receive treatment lenalidomide .</brief_summary>
	<brief_title>Efficacy NF-kB Inhibition Reducing Symptoms During Maintenance Therapy Multiple Myeloma Patients</brief_title>
	<detailed_description>Curcumin active ingredient spice turmeric . It may interfere production cytokine ( cause inflammation ) , may help reduce multiple symptom . A placebo drug . It look like study drug design treat disease illness . It design compare study drug learn study drug real effect . Study Groups : If agree take part study , randomly assign ( flip coin ) 1 2 group . Group 1 take curcumin . Group 2 take placebo . You equal chance assign group . No matter group , give standard care treat doctor . Neither study staff know receive study drug placebo . However , need safety , study staff able find receiving . Study Drug Administration : You take curcumin/placebo 2 time every day 12 hour apart . You begin take curcumin/placebo begin maintenance therapy lenalidomide . You give pamphlet information take curcumin/placebo . You must bring study capsule yet take clinic every study visit . Every 4 week call study cycle . Study Visits : Before begin treatment lenalidomide curcumin/placebo : - You teach use automate symptom assessment telephone program . - You complete 4 questionnaire pain symptom , quality life . In addition , personal information ( name , address , race , smoke history ) collect . Completing questionnaire take 20 minute . - You ask drug may take . - You ask well able perform normal activity daily live ( performance status ) . Telephone System Calls Symptom Monitoring : A telephone system call week time convenient . Using numeric key pad telephone , rate symptom interfere daily activity . Each phone call take 5 minute complete . You give brochure explain step complete symptom questionnaire telephone number call question problem telephone system . At start Cycle 4 End Study Visit : -You complete 3 questionnaire pain symptom quality life . The questionnaire take 20 minute complete . If reason , unable complete questionnaire automate symptom assessment telephone program , may able complete research staff , either phone routine clinic visit . Research staff talk regularly schedule visit cycle treatment lenalidomide . You ask side effect may drug take . Length Study : You take curcumin/placebo 6 month . You remain study 6-7 month ( depend clinic visit schedule ) . You take study intolerable side effect disease get bad . This investigational study . Curcumin FDA approve . At time , curcumin use research . Up 70 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Curcumin</mesh_term>
	<criteria>1 . Must histologically confirm diagnosis multiple myeloma . 2 . Must &gt; /= 18 year age . 3 . Must performance status ( ECOG PS ) 02 . 4 . Must qualify sign consent receive lenalidomide maintenance therapy MM . 5 . Must sign informed consent indicate aware investigational nature study , aware participation voluntary . 6 . Must also agree refrain use self prescribe curcumin course study . 7 . Must negative pregnancy test signing consent MM therapy . 1 . Unable understand symptom assessment willing participate study . 2 . Treatment carcinoma within last 5 year , except cure nonmelanoma skin treat insitu cervical cancer . 3 . Uncontrolled intercurrent illness include , limited , ongoing require IV antibiotic , cardiac disease ( NYHA class III IV heart failure ) , unstable angina pectoris , unstable cardiac arrhythmia tachycardia , psychiatric illness/ social situation would limit compliance study requirement exclude . 4 . Concurrent use coumadin low dose ( 1 mg ) coumadin use line patency . 5 . Concurrent use cimetidine , allopurinol , aluminium hydroxide magnesium hydroxidecontaining antacid Maalox . 6 . Sorivudine brivudine use within 4 week start study treatment . 7 . Gastric duodenal ulcer , gastric hyperacidity disorder . 8 . Currently receive anticoagulant ( heparin ) antiplatelets ( clopidogrel , ticlopidine , aspirin/dipyridamole ) 9 . INR &gt; 1.5 ( upper limit normal = 1.5 ) . 10 . History deep vein thrombosis . 11 . Received allogeneic transplant . 12 . Allergy turmeric , Curcumin , yellow dye . 13 . Bowel bile duct obstruction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>MM</keyword>
	<keyword>maintenance therapy</keyword>
	<keyword>lenalidomide</keyword>
	<keyword>bone marrow transplantation</keyword>
	<keyword>auto-HSCT</keyword>
	<keyword>Autologous Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>NF-kB inhibition</keyword>
	<keyword>reduce symptom</keyword>
	<keyword>maintenance chemotherapy</keyword>
	<keyword>inflammatory cytokine</keyword>
	<keyword>nuclear factor kappa B</keyword>
	<keyword>NF-kB</keyword>
	<keyword>interleukin</keyword>
	<keyword>IL-6</keyword>
	<keyword>tumor necrosis factor</keyword>
	<keyword>TNF-a</keyword>
	<keyword>NF-kB activation level</keyword>
</DOC>